Increased endothelin-1 reactivity and endothelial dysfunction in carotid arteries from rats with hyperhomocysteinemia

British Journal of Pharmacology

Volumn 157, Issue 4, 2009, Pages 568-580

  De Andrade, C R ^a   Leite, P F ^a   Montezano, A C ^a   Casolari, D A ^a   Yogi, A ^a   Tostes, R C ^a   Haddad, R ^b   Eberlin, M N ^b   Laurindo, F R M ^a   De Souza, H P ^a   Correa F M A ^a   DeOliveira, A M ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c Faculdade de Ciências Farmacêuticas de Ribeião Preto   (Brazil)

Author keywords

Calcium; Carotid artery; Endothelin 1; ET a receptors; ET b receptors; Hyperhomocysteinemia; Nitric oxide; Relaxation; Vasoconstriction

Indexed keywords

ACETYLCHOLINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; ENDOTHELIN CONVERTING ENZYME; HOMOCYSTEINE THIOLACTONE; INDOMETACIN; IODINE 125; MESSENGER RNA; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PHENYLEPHRINE; RHO KINASE; THROMBOXANE A2 RECEPTOR BLOCKING AGENT; ASPARTIC PROTEINASE; CALCIUM; ENDOTHELIN-CONVERTING ENZYME; METALLOPROTEINASE; NITROGEN OXIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY ENDOTHELIUM; ARTERY MEDIA; ARTICLE; BLOOD VESSEL REACTIVITY; CALCIUM TRANSPORT; CAROTID ARTERY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM INJURY; ENZYME ACTIVITY; GENE EXPRESSION; HYPERHOMOCYSTEINEMIA; IMMUNOHISTOCHEMISTRY; MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; RECEPTOR DENSITY; RECEPTOR GENE; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; BIOSYNTHESIS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; IN VITRO STUDY; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASOCONSTRICTION; VASODILATATION; WISTAR RAT;

ANIMALS; ASPARTIC ENDOPEPTIDASES; CALCIUM; CAROTID ARTERIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; HYPERHOMOCYSTEINEMIA; MALE; METALLOENDOPEPTIDASES; NITROGEN OXIDES; RATS; RATS, WISTAR; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; VASOCONSTRICTION; VASODILATION;

EID: 69249241679     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00165.x     Document Type: Article

References (44)

1. de Andrade CR, Fukada SY, Olivon VC, de Godoy MA, Haddad R, Eberlin MN et al. (2006). Alpha1D-adrenoceptor-induced relaxation on rat carotid artery is impaired during the endothelial dysfunction evoked in the early stages of hyperhomocysteinemia. Eur J Pharmacol 543: 83-91.
2. Au-Yeung KK, Woo CW, Sung FL, Yip JC, Siow YL, Karmin O (2004). Hyperhomocysteinemia activates nuclear factor-kappaB in endothelial cells via oxidative stress. Circ Res 94: 28-36.
3. Bagi Z, Ungvari Z, Szollar L, Koller A (2001). Flow-induced constriction in arterioles of hyperhomocysteinemic rats is due to impaired nitric oxide and enhanced thromboxane A(2) mediation. Arterioscler Thromb Vase Biol 21: 233-237. (Pubitemid 32125371)
4. Bagi Z, Ungvari Z, Koller A (2002). Xanthine oxidase-derived reactive oxygen species convert flow-induced arteriolar dilation to constriction in hyperhomocysteinemia: possible role of peroxynitrite. Arterioscler Thromb Vase Biol 22: 28-33. (Pubitemid 34076228)
5. Bonaventura D, Tirapelli CR, Haddad R, Hoehr NF, Eberlin MN, de Oliveira AM (2004). Chronic methionine load-induced hyperhomocysteinemia enhances rat carotid responsiveness for angiotensin II. Pharmacology 70: 91-99. (Pubitemid 38032502)
6. Brandes RP, Barton M, Philippens KM, Schweitzer G, Mugge A (1997). Endothelial-derived superoxide anion in pig coronary arteries; evidence from lucigenin chemiluminescence and histochemical techniques. J. Physiol 500: 331-342.
7. Bussemaker E, Pistrosch F, Förster S, Herbrig K, Gross P, Passauer J et al. (2007). Rho kinase contributes to basal vascular tone in humans: role of endothelium-derived nitric oxide. Am J. Physiol Heart Circ Physiol 293: H541-H547.
8. Chen C, Halkos ME, Surowiec SM, Conklin BS, Lin PH, Lumsden AB (2000). Effects of homocysteine on smooth muscle cell proliferation in both cell culture and artery perfusion culture models. J Surg Res 88: 26-33.
9. Chitaley K, Webb RC (2002). Nitric oxide induces dilation of rat aorta via inhibition of rho-kinase signaling. Hypertension 39: 438-442.
10. De Oliveira AM, Viswanathan M, Capsoni S, Heemskerk FM, Correa FM, Saavedra JM (1995). Characterization of endothelinA receptors in cerebral and peripheral arteries of the rat. Peptides 16: 139-144.
11. Demuth K, Atger V, Borderie D, Benoit MO, Sauvaget D, Lotersztajn S et al. (1999). Homocysteine decreases endothelin-1 production by cultured human endothelial cells. Eur f Biochem 263: 367-376. (Pubitemid 29337027)
12. Demuth K, Drunat S, Girerd X, Moatti N, Paul JL, Safar M et al. (2002). Homocysteine is the only plasma thiol associated with carotid artery remodeling. Atherosclerosis 165: 167-174. (Pubitemid 35223179)
13. Drunat S, Moatti N, Paul JL, Cogny A, Benoit MO, Demuth K (2001). Homocysteine-induced decrease in endothelin-1 production is initiated at the extracellular level and involves oxidative products. Eur Journal Biochem 268: 5287-5294. (Pubitemid 32948354)
14. Drunat S, Moatti N, Demuth K (2002). Homocysteine decreases endothelin-1 expression by interfering with the AP-I signaling pathway. Free Radie Biol Med 33: 659-668. (Pubitemid 35245838)
15. Dusitanond P, Eikelboom JW, Hankey GJ, Thorn J, Gilmore G, Loh K et al. (2005). Homocysteine-lowering treatment with folic acid, cobalamin, and pyridoxine does not reduce blood markers of inflammation, endothelial dysfunction, or hypercoagulability in patients with previous transient ischemic attack or stroke: a randomized substudy of the VITATOPS trial. Stroke 36: 144-146.
16. Haddad R, Sparrapan R, Eberlin MN (2006). Desorption sonic spray ionization for (high) voltage-free ambient mass spectrometry. Rapid Commun Mass Spedrom. 20: 2901-2905. (Pubitemid 44526628)
17. Hill CH, Mecham R, Starcher B (2002). Fibrillin-2 defects impair elastic fiber assembly in a homocysteinemic chick model. J Nutr 132: 2143-2150. (Pubitemid 34851641)
18. Ihara M, Noguchi K, Saeki T, Fukuruda T, Tsuchida S, Kimura S et at. (1992). Biological profiles of highly potent novel endothelin antagonists selective for ETA receptor. Life Sci 50: 247-255.
19. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, Saeki T et al. (1994). Biochemical and pharmacological profile of a newly-developed potent and selective endothelin B receptor antagonist, BQ-788. Proc Natl Acad Sci USA 20: 4892-4896.
20. Jin L, Ying Z, Webb RC (2004). Activation of Rho/Rho kinase signaling pathway by reactive oxygen species in rat aorta. Am J Physiol Heart Circ Physiol 287: H1495-H500.
21. Leite PF, Danilovic A, Model P, Dantas K, Marklund S, Dantas AP et at. (2003). Sustained decrease in superoxide dismutase activity underlies constrictive remodeling after balloon injury in rabbits. Arterioscler Thromb Vase Biol 23: 2197-2202.
22. Li Y, Zhu H, Kuppusamy P, Roubaud V, Zweier JL, Trush MA (1998). Validation of luclgenin (bis-N- methylacridinium) as a chemiluminescent probe for detecting superoxide anion radical for detecting superoxide anion radical production by enzymatic and cellular sources. J Biol Chem 273: 2015-2023.
23. Lopez-Ongil S, Senchak V, Saura M, Zaragoza C, Ames M, Ballermann B et al. (2000). Superoxide regulation of endothelin-converting enzyme. J Biol Chem 275: 26423-26427.
24. Luscher TF, Barton M (2000). Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 102: 2434-2440.
25. Masaki T (1995). Possible role of endothelin in endothelial regulation of vascular tone. Annu Rev Pharmacol Toxicol 35: 235-255.
26. Nakakuki T, Ito M, Iwasaki H, Kureishi Y, Okamoto R, Moriki N et al. (2005). Rho/Rho-kinase pathway contributes to C-reactive proteininduced plasminogen activator inhibitor-1 expression in endothelial cells. Arterioscler Thromb Vase Biol 25: 2088-2093. (Pubitemid 41416305)
27. Nazarali AJ, Gutkind JS, Saavedra JM (1989). Calibration of 1251-polymer standards with 1251-brain paste standards for use in quantitative receptor autoradiography. J Neurosa Methods 30: 247-253.
28. Nelson MT, Quayle JM (1995). Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268: C799-C822.
29. Okatani Y, Wakatsuki A, Reiter RJ (2001). Melatonin counteracts potentiation by homocysteine of KCL-induced vasoconstriction in human umbilical artery: relation to calcium influx. Biochem Biophys Res Commun 280: 940-944. (Pubitemid 32924524)
30. Pisciotta L, Cortese C, Gnasso A, Liberatoscioli L, Pastore A, Mannucci L et al. (2005). Serum homocysteine, methylenetetrahydrofoíate reductase gene polymorphism and cardiovascular disease in heterozygous familial hypercholesterolemia. Atherosclerosis 179: 333-338. (Pubitemid 40364628)
31. Powers RW, Majors AK, Cérula SL, Huber HA, Schmidt BP, Roberts JM (2003). Changes in markers of vascular injury in response to transient hyperhomocysteinemia. Metabolism 52: 501-507.
32. Pruefer D, Scalia R, Lefer AM (1999). Homocysteine provokes leukocyte-endothelium interaction by downregulation of nitric oxide. Gen Pharmacol 33: 487-498. (Pubitemid 30047154)
33. Refsum H, Ueland PM, Nygard O, Vollset SE (1998). Homocysteine and cardiovascular disease. Annu Rev Med 49: 31-62.
34. Robert K, Pages C, Ledru A, Delabar J, Caboche J, Janel N (2005). Regulation of extracellular signal-regulated kinase by homocysteine in hippocampus. Neuroscience 133: 925-935. (Pubitemid 40814601)
35. Takai M, Umemura K, Yamasaki K, Watanabe T, Fujitani Y, Oda K et al. (1992). A potent and specific agonist, Suc-[Glu9 Ala11,15]endothelin-1 (8-21), IRL 1620, for ETB receptor. Biochem Biophys Res Commun 184: 953-959.
36. Tirapelli CR, Casolari DA, Yogi A, Montezano AC, Tostes RC, Legros E et al. (2005). Functional characterization and expression of endothelin receptors in rat carotid artery: involvement of nitric oxide, a vasodilator prostanoid and the opening of K(+) channels in ET(B)induced relaxation. Br J. Pharmacol 146: 903-912.
37. Tirapelli CR, Casolari DA, Montezano AC, Yogi A, Tostes RC, Legros E et al. (2006). Ethanol consumption enhances endothelin-1-induced contraction in the isolated rat carotid. J Pharmacol Exp Ther 318: 819-827.
38. Tostes RC, Muscara MN (2005). Endothelin receptor antagonists: another potential alternative for cardiovascular diseases. Curr Drug Targets Cardiovasc Haematol Disord 5: 287-301.
39. Traupe T, Ortmann J, Munter K, Barton M (2003). Endothelial therapy of atherosclerosis and its risk factors. Curr Vase Pharmacol 1: 111-121.
40. Tyagi SC, Smiley LM, Mujumdar VS, Clonts B, Parker JL (1998). Reduction-oxidation (Redox) and vascular tissue level of homocysteine in human coronary atherosclerotic lesions and role in extracellular matrix remodeling and vascular tone. Mol Cell Biochem 181: 107-116. (Pubitemid 28127783)
41. Ungvari Z, Sarkadi-Nagy E, Bagi Z, Szollar L, Koller A (2000). Simultaneously increased TxA(2) activity in isolated arterioles and platelets of rats with hyperhomocysteinemia. Arterioscler Thromb Vase Biol 20: 1203-1208. (Pubitemid 30262919)
42. Viswanathan M, De Oliveira AM, Johren O, Saavedra JM (1997). Increased endothelin ET(A) receptor expression in rat carotid arteries after balloon injury. Peptides 18: 247-255. (Pubitemid 27224389)
43. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. (1988). A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415. (Pubitemid 18090241)
44. Weiss N, Heydrick SJ, Postea O, Keller C, Keaney JF Jr, Loscalzo J (2003). Influence of hyperhomocysteinemia on the cellular redox state - impact on homocysteine-induced endothelial dysfunction. Clin Chem Lab Med 41: 1455-1461. (Pubitemid 37493560)